GuShiio.com GuShiio.com has learned that the board of directors of medical technology company BioNexus Gene Lab has approved a financial reserve strategy with Ethereum (ETH) as the core, becoming the first Nasdaq-listed company to focus on Ethereum. BGLC also released the “Ethereum Strategy White Paper” to explain the basis for the decision and analyze Ethereum’s role in institutional adoption, proof-of-stake (PoS) pledge income, stablecoin transactions and the soon-to-be-upgraded Pectra protocol.
read the original
